Clinical trials: Plasmodium Falciparum Infection
Malaria, Falciparum, Plasmodium Falciparum
Clinical Practices for Treating Severe Malaria Caused by P. Falciparum
This study looks at how doctors in three hospitals in France treat patients with a serious form of malaria caused by Plasmodium falciparum. It focuses on cases where the level of malaria parasites in the blood is 4% or higher.
- Conditions
- Malaria, Falciparum, Plasmodium Falciparum, Antimalarials, Artemisinins
- Trial name
- NCT07027722
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Malaria, Anemia
RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants
The purpose of this trial is to evaluate the efficacy of weekly iron supplementation and the efficacy of malaria chemoprophylaxis from 2 to 12 months of age in infants living in an area of intense and perennial malaria…
- Trial name
- NCT00497471
- Testing
- Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone), iron (2 mg/kg/daily)
- Where
- Tanzania
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (NF54)
- Where
- Germany
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults.
- Trial name
- NCT01024686
- Testing
- p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Malaria
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate
The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute…
- Trial name
- JP015 (NCT01002183)
- Testing
- Fosmidomycin
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Jomaa Pharma GmbH
Malaria
Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with Plasmodium falciparum
- Trial name
- NCT06040346
- Testing
- Meplazumab for Injection
- Where
- Kenya
- Volunteers
- 60 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Falciparum Malaria
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum
The purpose of this study was to evaluate the effectiveness of the fixed combination of artesunate+mefloquine in the treatment of uncomplicated malaria caused by Plasmodium falciparum in the municipality of Cruzeiro do Sul, Juruá…
- Trial name
- NCT01144702
- Testing
- artesunate & mefloquine combination
- Where
- 2 sites in Brazil
- Volunteers
- 163 people
- Sponsor
- Oswaldo Cruz Foundation
Malaria
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Background: The disease malaria affects many people in Mali and other parts of Africa and the world. It is caused by germs spread by mosquito bites. Malaria may be mild.
- Trial name
- NCT03510481
- Testing
- PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL)
- Where
- Mali
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following…
- Trial name
- NCT02207816
- Testing
- Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Severe Falciparum Malaria
Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria
Background: Mortality from severe malaria remains ~15% despite the use of the most rapidly parasiticidal antimalarial therapy, artesunate. Adjunctive treatments may improve outcome.
- Trial name
- ARGISM (NCT00616304)
- Testing
- L-arginine hydrochloride, Normal saline
- Where
- Indonesia
- Volunteers
- 8 people
- Sponsor
- Menzies School of Health Research
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum, Malaria
DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Study to evaluate the efficacy of DSM265 as a causal prophylactic in a standardized and validated Human Challenge model using direct venous inoculation of aseptic, purified, cryopreserved, vialed Plasmodium falciparum sporozoites.
- Trial name
- NCT02450578
- Testing
- DSM265 400mg, Plasmodium falciparum sporozoite challenge, Malarone
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Malaria Vaccines
Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)
This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated…
- Trial name
- NCT01345240
- Testing
- GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix-B™ vaccine, Infanrix/Hib™ vaccine
- Where
- 2 sites in Burkina Faso, Ghana
- Volunteers
- 705 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Falciparum Malaria, Vivax Malaria
To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia
Multidrug resistant strains of P.falciparum and P.vivax are becoming increasingly prevalent in the Asia Pacific rim. To determine the efficacy of locally recommended antimalarial protocols in Papua, Indonesia, consecutive…
- Trial name
- NCT00157859
- Testing
- Chloroquine and sulphadoxine-pyrimethamine
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- Menzies School of Health Research
Malaria
Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria
This trial is part of a portfolio of studies designed to assess the clinical and operational performance of Abbott's NxTekTM Malaria Pf Plus and NxTekTM Malaria Pf/Pv Plus Rapid Test Devices.
- Trial name
- NCT05286359
- Testing
- NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device
- Where
- Ethiopia
- Volunteers
- 1,023 people
- Sponsor
- Abbott Rapid Dx
Malaria, Plasmodium Falciparum
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5
The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination.
- Trial name
- NCT02181088
- Testing
- ChAd63 RH5 low dose, ChAd63 RH5 full dose, MVA RH5 low dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
This three-part, first-in-human, healthy volunteer study aims to assess the safety and tolerability of the test medicine as well as how it is taken up by the body when given as single and multiple doses.
- Trial name
- NCT05507970
- Testing
- MMV367, MMV367 (Fed 440mg), MMV367 (Fasted 440mg)
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria,Falciparum
VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine
This is an open label, single-site, first-in-human, Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs25-IMX313 in Matrix-M1 adjuvant in healthy adults living in the UK…
- Trial name
- NCT04130282
- Testing
- Pfs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults
Malaria is caused by a germ that people get from the bites of some mosquitoes. It kills over 2 million people each year. Many of the drugs used to treat malaria do not work as well as they used to and researchers are exploring…
- Trial name
- NCT01026246
- Testing
- EBA-175 RII-NG Malaria Vaccine
- Where
- Ghana
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate
The purpose of this study is to compare the efficacy and safety of two antimalarial drug regimes, namely amodiaquine versus amodiaquine-artesunate, in the treatment of children with uncomplicated malaria.
- Trial name
- NCT00238017
- Testing
- amodiaquine-artesunate versus amodiaquine
- Where
- Ghana
- Volunteers
- 400 people
- Sponsor
- Charite University, Berlin, Germany